CURE Pharmaceutical Announces Product Development and Licensing Deal with Diverse International Pharmaceutical Company Meroven, Ltd.

OXNARD, Calif., March 21, 2017 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”) or (the “company”), a leading disruptive drug delivery technology company serving the pharmaceutical, biotech, veterinarian, medical foods markets, cannabinoid molecules and new chemical entities (NCEs), today announces a product development and license agreement with Dublin, Ireland-based Meroven, Ltd. (“Meroven”), for the development of oral thin film delivery for several molecules.

“We are excited to extend our reach into Ireland, and the Middle East, where Meroven intends to distribute these products.  Meroven is an established player in these markets, and we believe that the combination of their distribution and our proprietary drug delivery technology will help fill a void in these localities,” said Rob Davidson, CEO of CURE Pharmaceutical.  “We are pleased to be adding another OTC product to our production line and look forward to continued and expanded opportunities to work with Meroven.  In addition, we anticipate the announcement of additional deals in the short term, and look forward to sharing these milestones with our stockholders.”

As part of the agreement, CURE will formulate and manufacture oral thin film that delivers 1.25mg of Vitamin D3 utilizing the company’s proprietary formulation and manufacturing capabilities and its patented CureFilm™ technology.  Vitamin D is a fat-soluble vitamin that is naturally present in very few foods, added to others, and available as a dietary supplement. It is also produced endogenously when ultraviolet rays from sunlight strike the skin and trigger vitamin D synthesis.  Vitamin D promotes calcium absorption and is needed for bone growth. Vitamin D also prevents rickets in children and osteomalacia in adults. Together with calcium, vitamin D also helps protect older adults from osteoporosis.

“CURE Pharmaceutical has cultivated an exceptional reputation in terms of their efficiency and purity of its internal formulation and manufacturing processes,” added John Kiernan, Director of Meroven, Ltd.  “We look forward to a long and fruitful relationship with CURE and anticipate expanding the relationship above and beyond the current product.”

About CURE Pharmaceutical
Headquartered in Oxnard, CA, CURE Pharmaceutical is a fully integrated specialty pharmaceutical/bioscience company with disruptive proprietary drug delivery technologies for a broad range of molecules that it develops and manufactures in its state of the art cGMP facility.  CURE leverages novel drug delivery technologies to develop and commercialize new applications of proven therapeutics. CURE partners with pharmaceutical and biotech companies looking for new methods to deliver their proprietary molecules.   The technology enables differentiation within large therapeutic categories and potentially improves patient compliance while widening the therapeutic index.  CURE Pharmaceutical is traded under the symbol CURR.  For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com. 

About Meroven, Ltd.
Meroven is an Irish-based Pharmaceutical company that manufactures and trades in medical, pharmaceutical, OTC and other healthcare products. Meroven’s Corporate Head Office is based in Dublin, Ireland with regional representative sales offices throughout MENA and in particular the GCC. Meroven’s scope of business includes manufacturing pharmaceutical and healthcare products and trading in medical devices, durable medical goods and consumables.

Meroven has established strategic international partnerships with other leading companies in healthcare to support its vision. These partnerships span from USA, Canada, EU and the GCC. Meroven offers its clients western quality generic medicines that fill a niche, gap and/or offer innovative technologies for delivery.  For more information about Meroven, Ltd., please visit its website at www.meroven.com.

Forward-looking statements

This press release contains forward-looking statements, which are subject to a number of risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

Contact:
Jules Abraham
JQA Partners, Inc.
917-885-7378
[email protected]